

Isofol Medical AB (publ) publishes interim report, January–March 2022

GOTHENBURG, Sweden, May 12, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–March 2022 is now available on the company's website, www.isofolmedical.com.

First quarter, January–March 2022

- Net revenue amounted to TSEK 4,006 (5,215) and other revenue to TSEK 1 (0)
- The result for the period amounted to TSEK -47,874 (-42,662)
- Earnings per share amounted to SEK -0.30 (-0.51)
- Cash and cash equivalents on March 31 amounted to TSEK 332,035 (77,524)

Significant events during the first quarter 2022

- Jenny Sundqvist assumed her role as Chief Commercial Officer on January 1, 2022.

Significant events after the event of the period

- Isofol's Nomination Committee proposes the election of Jan Törnell as new Chairman of the Board at the Annual General Meeting on May 19, 2022.
- On April 22, Isofol announced that the process of analyzing study data from the AGENT study has begun.

CEO's comment:

"During the first quarter, Isofol performed many crucial and important activities to lay the foundation for the presentation of the forthcoming study results in the AGENT study. Having now passed the cut-off point that enables the start of the data analysis process, we see several milestones ahead, presentation of top-line data and later also final data", says CEO Ulf Jungnelius.

Audiocast, May 12, at 11:00 a.m. CEST

In conjunction with the publication of the interim report for the first quarter of 2022, Isofol invites investors, analysts, and media to an audiocast on May 12, 2022 at 11:00 a.m. CEST. The presentation will be held by Isofol's CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment the report, followed by a Q&A-session. The presentation will be held in English.

Date and time

May 12, 2022, at 11:00 a.m. CEST

Webcast link

<https://tv.streamfabriken.com/isofol-medical-q1-2022>

Phone number

To participate via telephone, please dial one of the numbers below.

SE: +46 8 50 55 83 53

UK: +44 333 300 92 68

US: +1 631 913 1422 PIN: 80079640#

The presentation will also be available on Isofol's website after the broadcast:

<https://isofolmedical.com/company-presentations/>

For more information, please contact**Isofol Medical AB (publ)**

Ulf Jungnelius, M.D., CEO

E-mail: jungnelius@isofolmedical.com

Telephone: +46 709-16 89 55

Gustaf Albèrt, CFO

E-mail: gustaf.albert@isofolmedical.com

Telephone: +46 709-16 83 02

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST, on May 12, 2022.

About arfolitixorin

Arfolitixorin is Isofol's proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global pivotal Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck & Cie, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq Stockholm.

www.isofolmedical.com